Document is current

Article History

Received: 6 June 2019

Accepted: 31 July 2019

First Online: 13 August 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: For activities outside of the submitted work, SA has received fees as speaker from ADA, Biomerieux, Cepheid, MB has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas Pharma, AstraZeneca, Bayer, Biomerieux, Cepheid, Cidara, Pfizer, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, Thermofisher and the Medicine Company, NP has received fees as speaker from MSD, Pfizer, Cepheid, Takeda, Shionogi, Angelini, Zambon, Becton & Dickinson, Johnson & Johnson, PV has served as a consultant for MSD, PFIZER, VENATORX, NABRIVA, GILEAD, THERMOFISHER and BIOMERIEUX and received payment for serving on the speaker’s bureau for MSD, PFIZER, CORREVIO and GILEAD, GMR has received honoraria for scientific advisory boards, travel and speaker’s bureau from Accelerate, Angelini, AstraZeneca, Basilea, Beckman Coulter, Biotest, Cepheid, Curetis, Elitech, Menarini, Merck, Nordic Pharma, Novartis, Pfizer, Qpex, Rempex, Roche, Thermo Fisher, VenatorX, Zambon; and research grants to the laboratory from from Accelerate, Alifax, Angelini, Arrow, AstraZeneca, Basilea, Becton-Dickinson, bioMérieux, Biotest, Cepheid, Checkpoints, Elitech, Estor, Liofilchem, Menarini, Merck, Nordic Pharma, Novartis, Pfizer, Rempex, Seegene, Shionogi, VenatorX, Zambon.PC and FT declare that they have no competing interests.